Host endothelial S1PR1 regulation of vascular permeability modulates tumor growth

American Journal of Physiology - Cell Physiology

Volumn 307, Issue 1, 2014, Pages

  Sarkisyan, Gor ^a   Gay, Laurie J ^a   Nguyen, Nhan ^a   Felding, Brunhilde H ^a   Rosen, Hugh ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Angiogenesis; Breast cancer; Metastasis; PyMT; Vasculature

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ENHANCED GREEN FLUORESCENT PROTEIN; RECEPTOR BLOCKING AGENT; RP 001; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG; W 146; 3 AMINO 4 (3 HEXYLPHENYLAMINO) 4 OXOBUTYLPHOSPHONIC ACID; 3-AMINO-4-(3-HEXYLPHENYLAMINO)-4-OXOBUTYLPHOSPHONIC ACID; ANILIDE; GREEN FLUORESCENT PROTEIN; PHOSPHONIC ACID DERIVATIVE; S1PR1 PROTEIN, MOUSE;

AGONIST; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TRANSPLANTATION; CIRCULATING TUMOR CELL; DRUG MEGADOSE; ENDOTHELIUM CELL; IMMUNOHISTOCHEMISTRY; MICRODIALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION; ANGIOGENESIS; ANIMAL; BREAST TUMOR; C57BL MOUSE; CAPILLARY PERMEABILITY; DRUG EFFECT; FEMALE; GENETICS; LUNG TUMOR; METABOLISM; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PYMT; S1PR1; TIME; TRANSGENIC MOUSE; TUMOR EMBOLISM; TUMOR VOLUME; VASCULARIZATION;

ANGIOGENESIS; BREAST CANCER; METASTASIS; PYMT; S1PR1; VASCULATURE;

ANILIDES; ANIMALS; BREAST NEOPLASMS; CAPILLARY PERMEABILITY; ENDOTHELIAL CELLS; FEMALE; GREEN FLUORESCENT PROTEINS; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASTIC CELLS, CIRCULATING; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPHOSPHONATES; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR BURDEN;

EID: 84903640427     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00043.2014     Document Type: Article

References (48)

1. Algire GH, Chalkley HW, Earle WE, Llegallais FY, Park HD, Shelton E, Schilling EL. Vascular reactions of normal and malignant tissues in vivo. III. Vascular reactions of mice to fibroblasts treated in vitro with methylcholanthrene. J Natl Cancer Inst 11: 555-580, 1950.
2. Baish JW, Jain RK. Cancer, angiogenesis and fractals. Nat Med 4: 984, 1998.
3. Baish JW, Jain RK. Fractals and cancer. Cancer Res 60: 3683-3688, 2000.
4. Baish JW, Stylianopoulos T, Lanning RM, Kamoun WS, Fukumura D, Munn LL, Jain RK. Scaling rules for diffusive drug delivery in tumor and normal tissues. Proc Natl Acad Sci USA 108: 1799-1803, 2011.
5. Cahalan SM, Gonzalez-Cabrera PJ, Nguyen N, Guerrero M, Cisar EAG, Leaf NB, Brown SJ, Roberts E, Rosen H. Sphingosine 1-phosphate receptor 1 [S1P(1)] upregulation and amelioration of experimental autoimmune encephalomyelitis by an S1P(1) antagonist. Mol Pharmacol 83: 316-321, 2013.
6. 1 agonist in S1P-eGFP knock-in mice. Nat Chem Biol 7: 254-256, 2011.
7. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307, 2011.
8. Chae SS, Paik JH, Furneaux H, Hla T. Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. J Clin Invest 114: 1082-1089, 2004.
9. Cierniewski CS, Malinowski M, Bednarek R, Cierniewska-Cieslak A. Adhesive and proteolytic phenotype of migrating endothelial cells induced by thymosin beta-4. Ann NY Acad Sci 1112: 123-139, 2007.
10. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30: 117-124, 2003.
11. DeClerck K, Elble RC. The role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy. Front Biosci 15: 213-225, 2010.
12. Ehrmann RL, Knoth M. Choriocarcinoma. Transfilter stimulation of vasoproliferation in the hamster cheek pouch. Studied by light and electron microscopy. J Natl Cancer Inst 41: 1329-1341, 1968.
13. Ekimov AI, Onushchenko AA. Quantum size effect in three-dimensional microscopic semiconductor crystals. J Exp Theor Phys Lett 34: 345, 1981.
14. Ephstein Y, Singleton PA, Chen W, Wang L, Salgia R, Kanteti P, Dudek SM, Garcia JG, Jacobson JR. Critical role of S1PR1 and integrin β4 in HGF/c-Met-mediated increases in vascular integrity. J Biol Chem 288: 2191-2200, 2013.
15. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2: 795-803, 2002.
16. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
17. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539-1544, 2007.
18. Gonzalez-Cabrera PJ, Cahalan SM, Nguyen N, Sarkisyan G, Leaf NB, Cameron MD, Kago T, Rosen H. S1P(1) receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis. Mol Pharmacol 81: 166-174, 2012.
19. Gonzalez-Cabrera PJ, Jo E, Sanna MG, Brown S, Leaf N, Marsolais D, Schaeffer MT, Chapman J, Cameron M, Guerrero M, Roberts E, Rosen H. Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions. Mol Pharmacol 74: 1308-1318, 2008.
20. Greenblatt M, Shubi P. Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. J Natl Cancer Inst 41: 111-124, 1968.
21. Gullino PM. Angiogenesis and oncogenesis. J Natl Cancer Inst 61: 639-643, 1978.
22. Igarashi J, Erwin PA, Dantas AP, Chen H, Michel T. VEGF induces S1P1 receptors in endothelial cells: Implications for cross-talk between sphingolipid and growth factor receptors. Proc Natl Acad Sci USA 100: 10664-10669, 2003.
23. Inoki I, Takuwa N, Sugimoto N, Yoshioka K, Takata S, Kaneko S, Takuwa Y. Negative regulation of endothelial morphogenesis and angiogenesis by S1P2 receptor. Biochem Biophys Res Commun 346: 293-300, 2006.
24. Jain RK, Booth MF. What brings pericytes to tumor vessels? J Clin Invest 112: 1134-1136, 2003.
25. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3: 24-40, 2006.
26. Jain RK. Determinants of tumor blood flow: a review. Cancer Res 48: 2641-2658, 1988.
27. Jain RK. Molecular regulation of vessel maturation. Nat Med 9: 685-693, 2003.
28. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62, 2005.
29. Kim KS, Kim S, Beack S, Yang JA, Yun SH, Hahn SK. In vivo real-time confocal microscopy for target-specific delivery of hyaluronic acid-quantum dot conjugates. Nanomedicine 8: 1070-1073, 2012.
30. Kimura T, Watanabe T, Sato K, Kon J, Tomura H, Tamama K, Kuwabara A, Kanda T, Kobayashi I, Ohta H, Ui M, Okajima F. Sphingosine 1-phosphate stimulates proliferation and migration of human endothelial cells possibly through the lipid receptors, Edg-1 and Edg-3. Biochem J 348: 71-76, 2000.
31. LaMontagne K, Littlewood-Evans A, Schnell C, O'Reilly T, Wyder L, Sanchez T, Probst B, Butler J, Wood A, Liau G, Billy E, Theuer A, Hla T, Wood J. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 66: 221-231, 2006.
32. Less JR, Skalak TC, Sevick EM, Jain RK. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res 51: 265-273, 1991.
33. Liao D, Johnson RS. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 26: 281-290, 2007.
34. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, Rosenfeldt HM, Nava VE, Chae SS, Lee MJ, Liu CH, Hla T, Spiegel S, Proia RL. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 106: 951-961, 2000.
35. Morris MA, Gibb DR, Picard F, Brinkmann V, Straume M, Ley K. Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720. Eur J Immunol 35: 3570-3580, 2005.
36. Murray CB, Kagan CR, Bawendi MG. Synthesis and characterization of monodisperse nanocrystals and close-packed nanocrystal assemblies. Ann Rev Mat Sci 30: 545-610, 2000.
37. Pries AR, Cornelissen AJM, Sloot AA, Hinkeldey M, Dreher MR, Höpfner M, Dewhirst MW, Secomb TW. Structural adaptation and heterogeneity of normal and tumor microvascular networks. PLoS Comput Biol 5: e1000394, 2009.
38. Pries AR, Höpfner M, le Noble F, Dewhirst MW, Secomb TW. The shunt problem: control of functional shunting in normal and tumour vasculature. Nat Rev Cancer 10: 587-593, 2010.
39. Rosen H, Stevens RC, Hanson M, Roberts E, Oldstone MB. Sphingosine-1-phosphate and its receptors: structure, signaling, and influence. Annu Rev Biochem 82: 637-662, 2013.
40. Sanna MG, Wang SK, Gonzalez-Cabrera PJ, Don A, Marsolais D, Matheu MP, Wei SH, Parker I, Jo E, Cheng WC, Cahalan MD, Wong CH, Rosen H. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol 2: 434-441, 2006.
41. Sarkisyan G, Cahalan S, Gonzalez-Cabrera P, Leaf N, Rosen H. Real-time differential labeling of blood, interstitium and lymphatic and single-field analysis of vasculature dynamics in vivo. Am J Physiol Cell Physiol 302: C1460-C1468, 2012.
42. Semenza GL. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20: 51-56, 2010.
43. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29: 625-634, 2010.
44. Shoham AB, Malkinson G, Krief S, Shwartz Y, Ely Y, Ferrara N, Yaniv K, Zelzer E. S1P1 inhibits sprouting angiogenesis during vascular development. Development 139: 3859-3869, 2012.
45. Tarrasón G, Aulí M, Mustafa S, Dolgachev V, Domènech MT, Prats N, Domínguez M, López R, Aguilar N, Calbet M, Pont M, Milligan G, Kunkel SL, Godessart N. The sphingosine-1-phosphate receptor-1 antagonist, W146, causes early and short-lasting peripheral blood lymphopenia in mice. Int Immunopharmacol 11: 1773-1779, 2011.
46. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64: 3731-3736, 2004.
47. Yonesu K, Kawase Y, Inoue T, Takagi N, Tsuchida J, Takuwa Y, Kumakura S, Nara F. Involvement of sphingosine-1-phosphate and S1P1 in angiogenesis: analyses using a new S1P1 antagonist of nonsphingosine-1-phosphate analog. Biochem Pharmacol 77: 1011-1020, 2009.
48. Zhou WQ, Zhang HJ, Jin J, Li Y, Li C, Chen XG. [Immunosuppressive effect of S1P1 receptor agonist FTY720]. Yao Xue Xue Bao 47: 546-550, 2012.